Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Publication | Open Access

DOI Full Paper Access

Citations

References

2018

Year

Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra,

Cardiovascular Diabetology